Maria Cristina Foss-Freitas
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Maria Cristina Foss-Freitas has a total of 34 co-authors. Here are the top co-authors by number of shared publications:
- Elif Arioglu Oral
Division of Metabolism, Endocrinology and Diabetes, Department of Internal Medicine, University of Michigan Medical School , Ann Arbor, MI 48109
2 shared publications - Natália Rossin Guidorizzi
Brazilian Group for the Study of Inherited and Acquired Lipodystrophies (BRAZLIPO), Fortaleza, Brazil
2 shared publications - Adam H. Neidert
Caswell Diabetes Institute and Metabolism, Endocrinology and Diabetes Division, Department of Internal Medicine, University of Michigan Medical School, Ann Arbor, Michigan, USA
1 shared publication Adam Neidert
Division of Metabolism, Endocrinology and Diabetes, University of Michigan, Ann Arbor, Michigan, USA
1 shared publicationAmanda Caboclo Flor
Brazilian Group for the Study of Inherited and Acquired Lipodystrophies (BRAZLIPO), Fortaleza, Brazil
1 shared publicationAmy E. Rothberg
Division of Metabolism, Endocrinology and Diabetes, University of Michigan, Ann Arbor, Michigan, USA
1 shared publication
Latest Publications
- Open Access
- 29 January 2026
- Published by American Society for Clinical Investigation in Journal of Clinical Investigation
- Vol. 136 (6)
EBF2 variant identified in a patient with atypical partial lipodystrophy causes adipose fibrosis and dysfunction
Lipodystrophy (LD) syndromes are characterized by loss of adipose tissue (AT), leading to insulin resistance and the development of metabolic syndrome. We identified a heterozygous nonsense variant in early B cell factor 2 ( EBF2 ) (Chr8:26033143C>A, NM_022659.4: c.493G>T, p.E165X) in a patient with atypical partial LD (PLD). The EBF family is crucial for the differentiation and function of various mesenchymal tissues. Through in vitro and in vivo disease models, we discovered that this variant limited adipocyte differentiation and hampered AT remodeling. Heterozygous-knockin ( Ebf2 E165X/+ ) mice showed restricted adipogenesis and defective extracellular matrix remodeling during the post-weaning period and high-fat diet–induced (HFD-induced) AT expansion. A HFD caused abnormal adipocyte hypertrophy, decreased the expression of adiponectin and leptin, and led to glucose intolerance in Ebf2 E165X/+ mice. Furthermore, key mitochondrial genes involved in fatty acid metabolism and oxidation were downregulated specifically in Ebf2 E165X/+ AT. Our results suggest that EBF2 dysfunction caused by this nonsense variant drives disease pathology, establishing a connection between EBF2 disruption and an atypical form of LD.
- 29 January 2026
- Published by American Society for Clinical Investigation in Journal of Clinical Investigation
- Vol. 136 (6)
Open AccessEBF2 variant identified in a patient with atypical partial lipodystrophy causes adipose fibrosis and dysfunction
Lipodystrophy (LD) syndromes are characterized by loss of adipose tissue (AT), leading to insulin resistance and the development of metabolic syndrome. We identified a heterozygous nonsense variant in early B cell factor 2 ( EBF2 ) (Chr8:26033143C>A, NM_022659.4: c.493G>T, p.E165X) in a patient with atypical partial LD (PLD). The EBF family is crucial for the differentiation and function of various mesenchymal tissues. Through in vitro and in vivo disease models, we discovered that this variant limited adipocyte differentiation and hampered AT remodeling. Heterozygous-knockin ( Ebf2 E165X/+ ) mice showed restricted adipogenesis and defective extracellular matrix remodeling during the post-weaning period and high-fat diet–induced (HFD-induced) AT expansion. A HFD caused abnormal adipocyte hypertrophy, decreased the expression of adiponectin and leptin, and led to glucose intolerance in Ebf2 E165X/+ mice. Furthermore, key mitochondrial genes involved in fatty acid metabolism and oxidation were downregulated specifically in Ebf2 E165X/+ AT. Our results suggest that EBF2 dysfunction caused by this nonsense variant drives disease pathology, establishing a connection between EBF2 disruption and an atypical form of LD.
- Open Access
- 3 June 2024
- Published by Frontiers Media SA in Frontiers in Endocrinology
- Vol. 15, 1359211
Comprehensive analysis of morbidity and mortality patterns in familial partial lipodystrophy patients: insights from a population study
Background: There is a lack of information on the clinical and molecular presentation of familial partial lipodystrophy (FPLD), a rare genetic disorder characterized by partial subcutaneous fat loss.Objective: This study aimed to provide a comprehensive assessment of the clinical, metabolic, and genetic features of FPLD in the Brazilian population.Methods: In a multicenter cross-sectional investigation we evaluated patients with FPLD across five Brazilian reference centers for lipodystrophies. Diagnosis of FPLD was made by clinical evaluation and genetic confirmation. Data on genetic, clinical, and metabolic characteristics were captured. Statistical analysis involved the utilization of the Kruskal-Wallis test to identify differences.Results: The study included 106 patients with genetic confirmation of FPLD. The mean age was 44 ± 15 years, and they were predominantly female (78.3%). LMNA pathogenic variants were identified in 85.8% of patients, PPARG in 10.4%, PLIN1 in 2.8%, and MFN2 in 0.9%. Diabetes mellitus (DM) was highly prevalent (57.5%), affecting 54 females (50.9%). Median triglycerides levels were 199 mg/dL (54–2724 mg/dL), severe hypertriglyceridemia (≥ 500 mg/dL) was found in 34.9% and pancreatitis in 8.5%. Metabolic-associated fatty liver disease (MAFLD) was observed in 56.6%, and cardiovascular disease in 10.4%. The overall mortality rate was 3.8%, due to cardiovascular events.Conclusion: This study presents an extensive cohort of Brazilian patients with FPLD, predominantly DM with several multisystem complications. A comprehensive characterization of lipodystrophy syndromes is crucial for effective patient management and care.
- 3 June 2024
- Published by Frontiers Media SA in Frontiers in Endocrinology
- Vol. 15, 1359211
Open AccessComprehensive analysis of morbidity and mortality patterns in familial partial lipodystrophy patients: insights from a population study
Background: There is a lack of information on the clinical and molecular presentation of familial partial lipodystrophy (FPLD), a rare genetic disorder characterized by partial subcutaneous fat loss.Objective: This study aimed to provide a comprehensive assessment of the clinical, metabolic, and genetic features of FPLD in the Brazilian population.Methods: In a multicenter cross-sectional investigation we evaluated patients with FPLD across five Brazilian reference centers for lipodystrophies. Diagnosis of FPLD was made by clinical evaluation and genetic confirmation. Data on genetic, clinical, and metabolic characteristics were captured. Statistical analysis involved the utilization of the Kruskal-Wallis test to identify differences.Results: The study included 106 patients with genetic confirmation of FPLD. The mean age was 44 ± 15 years, and they were predominantly female (78.3%). LMNA pathogenic variants were identified in 85.8% of patients, PPARG in 10.4%, PLIN1 in 2.8%, and MFN2 in 0.9%. Diabetes mellitus (DM) was highly prevalent (57.5%), affecting 54 females (50.9%). Median triglycerides levels were 199 mg/dL (54–2724 mg/dL), severe hypertriglyceridemia (≥ 500 mg/dL) was found in 34.9% and pancreatitis in 8.5%. Metabolic-associated fatty liver disease (MAFLD) was observed in 56.6%, and cardiovascular disease in 10.4%. The overall mortality rate was 3.8%, due to cardiovascular events.Conclusion: This study presents an extensive cohort of Brazilian patients with FPLD, predominantly DM with several multisystem complications. A comprehensive characterization of lipodystrophy syndromes is crucial for effective patient management and care.
- Open Access
- 30 April 2024
- Published by Open Source Publications in Open Journal of Clinical and Medical Case Reports
- Vol. 10 (11)
Investigation of lipodystrophy in a 3-year-old and 6-month-old child: A case report
This report delineates the case of a 3-year-old and 6-month-old child exhibiting noteworthy weight loss post-vaccination, succeeded by modest adipose tissue gain and subsequent phenotype deterioration following a viral episode. Additionally, the patient presents phlebomegaly, muscular hypertrophy, and irritability linked to hyperphagia. Despite extensive investigation encompassing celiac disease exclusion, the prevailing diagnostic hypothesis is acquired generalized lipodystrophy.
- 30 April 2024
- Published by Open Source Publications in Open Journal of Clinical and Medical Case Reports
- Vol. 10 (11)
Open AccessInvestigation of lipodystrophy in a 3-year-old and 6-month-old child: A case report
This report delineates the case of a 3-year-old and 6-month-old child exhibiting noteworthy weight loss post-vaccination, succeeded by modest adipose tissue gain and subsequent phenotype deterioration following a viral episode. Additionally, the patient presents phlebomegaly, muscular hypertrophy, and irritability linked to hyperphagia. Despite extensive investigation encompassing celiac disease exclusion, the prevailing diagnostic hypothesis is acquired generalized lipodystrophy.
- Open Access
- 12 November 2023
- Published by S. Karger AG in Obesity Facts
- Vol. 17 (1) , 103-108
A Very-Low-Calorie Diet Can Cause Remission of Diabetes Mellitus and Hypertriglyceridemia in Familial Partial Lipodystrophy
There is no strong evidence that any specific diet is the preferred treatment for lipodystrophy syndromes. Here we remark on the benefits of a very-low-calorie diet (VLCD) in a patient with familial partial lipodystrophy type 2 (FPLD2). A 38-year-old female diagnosed with FPLD2, with a history of multiple comorbidities, underwent 16 weeks of VLCD with a short-term goal of improving her metabolic state rapidly to achieve pregnancy by in vitro fertilization (IVF). We observed a reduction of 12.3 kg in body weight and 1.4% in hemoglobin A1c. The decrease in the area under the curves of insulin (−33.2%), triglycerides (−40.7%), and free fatty acids (−34%) were very remarkable. Total body fat was reduced by 16%, and liver fat by 80%. Her egg retrieval rate and quality during IVF were far superior to past hyperstimulation. Our data encourage the use of this medical approach for other patients with similar metabolic and reproductive abnormalities due to adipose tissue insufficiency.
- 12 November 2023
- Published by S. Karger AG in Obesity Facts
- Vol. 17 (1) , 103-108
Open AccessA Very-Low-Calorie Diet Can Cause Remission of Diabetes Mellitus and Hypertriglyceridemia in Familial Partial Lipodystrophy
There is no strong evidence that any specific diet is the preferred treatment for lipodystrophy syndromes. Here we remark on the benefits of a very-low-calorie diet (VLCD) in a patient with familial partial lipodystrophy type 2 (FPLD2). A 38-year-old female diagnosed with FPLD2, with a history of multiple comorbidities, underwent 16 weeks of VLCD with a short-term goal of improving her metabolic state rapidly to achieve pregnancy by in vitro fertilization (IVF). We observed a reduction of 12.3 kg in body weight and 1.4% in hemoglobin A1c. The decrease in the area under the curves of insulin (−33.2%), triglycerides (−40.7%), and free fatty acids (−34%) were very remarkable. Total body fat was reduced by 16%, and liver fat by 80%. Her egg retrieval rate and quality during IVF were far superior to past hyperstimulation. Our data encourage the use of this medical approach for other patients with similar metabolic and reproductive abnormalities due to adipose tissue insufficiency.